| Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer (NCT07707674) | Evopoint Biosciences Inc. | 2026-07-30 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer (NCT07730580) | Evopoint Biosciences Inc. | 2026-07-13 |
| Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma (NCT07545603) | Evopoint Biosciences Inc. | 2026-02-14 |
| A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor (NCT07327294) | Evopoint Biosciences Inc. | 2026-01-31 |
| Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma (NCT07730515) | Evopoint Biosciences Inc. | 2025-08-15 |
| A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment (NCT06987500) | Evopoint Biosciences Inc. | 2025-04-11 |
| A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT06776952) | Evopoint Biosciences Inc. | 2025-04-10 |
| To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (NCT06702605) | Evopoint Biosciences Inc. | 2024-11-01 |
| Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (NCT06799637) | Evopoint Biosciences Inc. | 2023-12-01 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) (NCT06022757) | Evopoint Biosciences Inc. | 2023-09-20 |
| Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer (NCT06702995) | Evopoint Biosciences Inc. | 2023-04-19 |
| Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40) (NCT05204368) | Evopoint Biosciences Inc. | 2023-03-30 |
| Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) (NCT05204563) | Evopoint Biosciences Inc. | 2022-07-31 |
| To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors (NCT06558513) | Evopoint Biosciences Inc. | 2021-08-03 |
| Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects (NCT04802863) | Evopoint Biosciences Inc. | 2021-03-25 |
| To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females. (NCT04801043) | Evopoint Biosciences Inc. | 2021-03-02 |
| Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function (NCT04787562) | Evopoint Biosciences Inc. | 2021-02-25 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin (NCT04482569) | Evopoint Biosciences Inc. | 2020-07-10 |
| The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject (NCT04040907) | Evopoint Biosciences Inc. | 2019-11-13 |
| Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors (NCT03901950) | Evopoint Biosciences Inc. | 2019-07-01 |